Flobufen
Based on 1 Customer Validation
Flobufen (VUFB 16066) is a non-steroidal anti-inflammatory agent and cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) inhibitor agent. Flobufen inhibits alloantigen-driven cellular immune responses and stimulates phagocytosis of peritoneal cells. Flobufen can improve immunopathological disorders and has an inhibitory effect on rheumatoid arthritis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 112344-52-2
- Formule: C17H14F2O3
- Masse moléculaire:304.29
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Activité biologique
Description
IC50 & Target
COX; 5-LOX[1]
Chemical Information
-
CAS No. 112344-52-2
-
Appearance Solid
-
Masse moléculaire 304.29
-
Formule C17H14F2O3
-
SMILES
FC1=C(C2=CC=C(C(CC(C)C(O)=O)=O)C=C2)C=CC(F)=C1
-
Synonyms
VUFB 16066
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
In Vitro:
DMSO : 40 mg/mL (131.45 mM; ultrasonic and adjust pH to 9 with 1 M NaOH; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocole
-
Phagocytosis Functional Assay
A phagocytosis functional assay measures the ability of phagocytic cells, such as neutrophils, macrophages, monocytes, or microglia/macrophages, to bind and internalize particulate targets including bacteria, yeast particles, beads, or myelin particles. Fluorescent flow-cytometry assays detect target uptake as fluorescence associated with gated phagocytes, while pH-sensitive dyes such as pHrodo increase signal in acidic phagosomal compartments and therefore preferentially report internalized particles rather than particles remaining outside the cell. Microscopy or high-content imaging can be used to confirm intracellular localization and, in some protocols, to follow uptake kinetics.
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureté et documentation
-
Fiche technique (270 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Kvasnicková E, et al. Metabolic pathways of flobufen-a new antirheumatic and antiarthritic drug. Interspecies comparison. Exp Toxicol Pathol. 1999 Jul;51(4-5):352-6. [Content Brief]
[2]. Panajotova V, et al. Pharmacological profile of the novel potent antirheumatic 4-(2',4'-difluorobiphenyl-4-yl)-2-methyl-4-oxobutanoic acid. Arzneimittelforschung. [Content Brief]
[3]. Drsata J, et al. Inhibice dekarboxylázy aromatických aminokyselin protizánĕtlivými látkami flobufenem a kyselinou 2',4'-difluorbifenyl-4-yloctovou [Inhibition of aromatic amino acid decarboxylases by the anti-inflammatory agent flobufen and 2',4'-difluorbiphenyl-4-acetic acid]. Cesk Farm. 1989 Nov;38(9):407-10. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2863 mL | 16.4317 mL | 32.8634 mL | 82.1585 mL |
| 5 mM | 0.6573 mL | 3.2863 mL | 6.5727 mL | 16.4317 mL | |
| 10 mM | 0.3286 mL | 1.6432 mL | 3.2863 mL | 8.2158 mL | |
| 15 mM | 0.2191 mL | 1.0954 mL | 2.1909 mL | 5.4772 mL | |
| 20 mM | 0.1643 mL | 0.8216 mL | 1.6432 mL | 4.1079 mL | |
| 25 mM | 0.1315 mL | 0.6573 mL | 1.3145 mL | 3.2863 mL | |
| 30 mM | 0.1095 mL | 0.5477 mL | 1.0954 mL | 2.7386 mL | |
| 40 mM | 0.0822 mL | 0.4108 mL | 0.8216 mL | 2.0540 mL | |
| 50 mM | 0.0657 mL | 0.3286 mL | 0.6573 mL | 1.6432 mL | |
| 60 mM | 0.0548 mL | 0.2739 mL | 0.5477 mL | 1.3693 mL | |
| 80 mM | 0.0411 mL | 0.2054 mL | 0.4108 mL | 1.0270 mL | |
| 100 mM | 0.0329 mL | 0.1643 mL | 0.3286 mL | 0.8216 mL |